Last reviewed · How we verify
MK0364
At a glance
| Generic name | MK0364 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED) (PHASE2, PHASE3)
- A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007) (PHASE2)
- An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006) (PHASE2)
- A Study of MK0364 in Obese Patients (0364-014) (PHASE3)
- An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED) (PHASE3)
- An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED) (PHASE3)
- A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED) (PHASE3)
- A Weight Maintenance Study in Obese Patients (0364-012)(TERMINATED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0364 CI brief — competitive landscape report
- MK0364 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI